Page last updated: 2024-11-12

hydroxymatairesinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydroxymatairesinol: a plant lignan from Norway spruce (Picea abies); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10948757
CHEMBL ID513565
SCHEMBL ID13505576
MeSH IDM0377674

Synonyms (14)

Synonym
hydroxymatairesinol
CHEMBL513565
7-hydroxymatairesinol
UKHWOLNMBQSCLJ-BIENJYKASA-N
SCHEMBL13505576
(3r,4r)-4-[(s)-hydroxy-(4-hydroxy-3-methoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
347359-71-1
DTXSID70942387
Q15411031
2(3h)-furanone, dihydro-4-((s)-hydroxy(4-hydroxy-3-methoxyphenyl)methyl)-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3r,4r)-
(3r,4r)-4-((s)-hydroxy(4-hydroxy-3-methoxyphenyl)methyl)-3-((4-hydroxy-3-methoxyphenyl)methyl)oxolan-2-one
.alpha.-hydroxymatairesinol
(-)-7-hydroxymatairesinol
7(s)-hydroxymatairesinol

Research Excerpts

Overview

7-Hydroxymatairesinol (7-HMR) is a plant lignan abundant in various concentrations in plant foods. It is shown to be a readily available starting material for the preparation of norlignans of the imperanene, vitrofolal and noralashinol family.

ExcerptReferenceRelevance
"7-Hydroxymatairesinol (7-HMR) is a plant lignan abundant in various concentrations in plant foods. "( 7-Hydroxymatairesinol improves body weight, fat and sugar metabolism in C57BJ/6 mice on a high-fat diet.
Andreoli, R; Archetti, I; Biasiotto, G; Cadei, M; De Palma, G; Di Lorenzo, D; Luzzani, M; Monti, E; Mozzoni, P; Pacchetti, B; Predolini, F; Serana, F; Smeds, A; Zanella, I, 2018
)
1.92
"Hydroxymatairesinol is shown to be a readily available starting material for the preparation of norlignans of the imperanene, vitrofolal and noralashinol family."( 9-Norlignans: Occurrence, Properties and Their Semisynthetic Preparation from Hydroxymatairesinol.
Eklund, P; Raitanen, JE, 2019
)
1.46

Toxicity

ExcerptReferenceRelevance
" These changes, which have also been reported for other (flaxseed) lignans, were not considered to represent adverse effects."( A thirteen week dietary toxicity study with 7-hydroxymatairesinol potassium acetate (HMRlignan) in rats.
Korte, H; Lina, B; Nyman, L; Unkila, M, 2005
)
0.59

Pharmacokinetics

ExcerptReferenceRelevance
"A single-blind, parallel, pharmacokinetic and dose-comparison study was conducted on 22 postmenopausal females not receiving hormone replacement therapy."( Pharmacokinetics and bioavailability of plant lignan 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: a single-blinded, parallel, dose-comparison study.
Brown, DJ; Hardy, M; Tan, MO; Udani, JK, 2013
)
0.64

Bioavailability

ExcerptReferenceRelevance
" to rats and dogs (daily doses up to 2000 and 665 mg/kg, respectively); HM-3000 was shown to be well absorbed (> 50% of the dose) and rapidly eliminated."( Antioxidant and antitumor effects of hydroxymatairesinol (HM-3000, HMR), a lignan isolated from the knots of spruce.
Ahotupa, M; Hirsinummi, R; Kangas, L; Korte, H; Laatikainen, R; Mutanen, M; Perälä, M; Saarinen, N; Santti, R; Soininen, P; Unkila, M, 2002
)
0.59
" The purpose of this study was to evaluate the bioavailability of a proprietary 7-HMR product (HMRlignan, Linnea SA, Locarno, Switzerland) through measurement of lignan metabolites and metabolic precursors."( Pharmacokinetics and bioavailability of plant lignan 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: a single-blinded, parallel, dose-comparison study.
Brown, DJ; Hardy, M; Tan, MO; Udani, JK, 2013
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID426070Induction of apoptosis in human EBV deficient BL41 cells assessed as condensed and fragmented nuclei at 25 to 100 uM after 18 hrs by epifluorescent microscopy2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
A novel and efficient synthesis of highly oxidized lignans by a methyltrioxorhenium/hydrogen peroxide catalytic system. Studies on their apoptogenic and antioxidant activity.
AID402553Metabolic stability in Sprague-Dawley rat assessed as conversion to hydroxymatairesinol level at 50 mg/kg, po after 48 hrs2004Journal of natural products, Jun, Volume: 67, Issue:6
A new lariciresinol-type butyrolactone lignan derived from hydroxymatairesinol and its identification in spruce wood.
AID1377035Antioxidant activity assessed as DPPH radical scavenging activity at test compound/DPPH volume ratio 1:1 after 1 hr by UV-spectrophotometric method2017Journal of natural products, 06-23, Volume: 80, Issue:6
Derivatives of the Lignan 7'-Hydroxymatairesinol with Antioxidant Properties and Enhanced Lipophilicity.
AID426071Induction of apoptosis in human E2R cells expressing EBV assessed as condensed and fragmented nuclei at 25 to 100 uM after 18 hrs by epifluorescent microscopy2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
A novel and efficient synthesis of highly oxidized lignans by a methyltrioxorhenium/hydrogen peroxide catalytic system. Studies on their apoptogenic and antioxidant activity.
AID402549Metabolic stability in Sprague-Dawley rat assessed as urinary excretion of hydroxymatairesinol at 50 mg/kg, po after 48 hrs2004Journal of natural products, Jun, Volume: 67, Issue:6
A new lariciresinol-type butyrolactone lignan derived from hydroxymatairesinol and its identification in spruce wood.
AID1377033Lipophilicity, log Kw of the compound by reversed-phase UHPLC analysis2017Journal of natural products, 06-23, Volume: 80, Issue:6
Derivatives of the Lignan 7'-Hydroxymatairesinol with Antioxidant Properties and Enhanced Lipophilicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (57.58)29.6817
2010's12 (36.36)24.3611
2020's2 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.53 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.89 (4.65)
Search Engine Demand Index41.67 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (29.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]